Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China

被引：0
作者：
Huang, Kun [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Pediat, Sch Med, 1367 Wenyi West Rd, Hangzhou 311121, Zhejiang, Peoples R China
来源：
ADVANCES IN THERAPY | 2024年 / 41卷 / 04期
关键词：
Hemophilia A; Pharmacokinetics; Cost-effectiveness; Prophylaxis; Bleeding;
D O I：
10.1007/s12325-024-02786-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：1759 / 1761
页数：3
相关论文
共 50 条
  • [21] The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study
    Grazzi, Enrico Ferri
    Sun, Shawn X.
    Burke, Tom
    O'Hara, Jamie
    [J]. JOURNAL OF BLOOD MEDICINE, 2022, 13 : 505 - 516
  • [22] Cefuroxime (Aprokam®) in the Prophylaxis of Postoperative Endophthalmitis After Cataract Surgery Versus Absence of Antibiotic Prophylaxis: A Cost-Effectiveness Analysis in Poland
    Rekas, Marek
    Mlynczak, Katarzyna
    Dobrowolska, Iwona
    Niewada, Maciej
    Golicki, Dominik
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2020, 22 : 115 - 121
  • [23] PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A
    Pasca, Samantha
    Milan, Marta
    Sarolo, Lucia
    Zanon, Ezio
    [J]. THROMBOSIS RESEARCH, 2017, 157 : 58 - 63
  • [24] Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A
    Miners, A.
    [J]. HAEMOPHILIA, 2009, 15 (04) : 881 - 887
  • [25] Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy
    Coppola, A.
    D'Ausilio, A.
    Aiello, A.
    Amoresano, S.
    Toumi, M.
    Mathew, P.
    Tagliaferri, A.
    [J]. HAEMOPHILIA, 2017, 23 (03) : 422 - 429
  • [26] Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan
    Mizushima, Daisuke
    Nagai, Yoshino
    Mezzio, Dylan
    Harada, Keisuke
    Piao, Yi
    Barnieh, Lianne
    El Moustaid, Fadoua
    Cawson, Matthew
    Taniguchi, Toshibumi
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 886 - 893
  • [27] Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico
    Salinas-Escudero, Guillermo
    Martinez-Valverde, Silvia
    Reyes-Lopez, Alfonso
    Garduno-Espinosa, Juan
    Munoz-Hernandez, Onofre
    Granados-Garcia, Victor
    Rely, Kely
    [J]. SALUD PUBLICA DE MEXICO, 2012, 54 (01): : 47 - 59
  • [28] Antibiotic prophylaxis at the time of dental implant placement: a cost-effectiveness analysis
    Khrystyna Zhurakivska
    Lucio Lo Russo
    Lorenzo Lo Muzio
    Vito Carlo Alberto Caponio
    Luigi Laino
    Claudia Arena
    Nicola Cirillo
    Giuseppe Troiano
    [J]. BMC Health Services Research, 22
  • [29] Antibiotic prophylaxis at the time of dental implant placement: a cost-effectiveness analysis
    Zhurakivska, Khrystyna
    Lo Russo, Lucio
    Lo Muzio, Lorenzo
    Caponio, Vito Carlo Alberto
    Laino, Luigi
    Arena, Claudia
    Cirillo, Nicola
    Troiano, Giuseppe
    [J]. BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [30] A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom
    Bentley A.
    Filipovic I.
    Gooch K.
    Büsch K.
    [J]. Health Economics Review, 3 (1) : 1 - 12
12345